Sembragiline clinical trials
Also written RO4602522.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses sembragiline is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2012 | 3 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Hoffmann-La Roche (4) · Evotec Neurosciences GmbH (2)
Often tested with
Tested in the same studies.
Moxifloxacin (1) · Nicotine Replacement (1)
Related medicines
As reviewed, each with the page that says it.
- One of MAO inhibitors (MAOIs) source
Studies
Open first, then newest update. How each study uses sembragiline is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease TherapyCompletedPhase 2Hoffmann-La RocheNCT01677754Written as RO4602522
- A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01701089Written as RO4602522
- A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc IntervalCompletedPhase 1Hoffmann-La RocheNCT02104648Written as RO4602522
- A Single Dose Study of Radiolabeled RO4602522 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01631422Written as RO4602522
- Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.CompletedPhase 2Evotec Neurosciences GmbHNCT00738595Written as EVT 302
- Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of CigarettesCompletedPhase 2Evotec Neurosciences GmbHNCT00622752Written as EVT 302, 10 mg
Given beside what is tested · 1 — sembragiline is usual care or a partner of the new treatment
Codes
What other systems call sembragiline · ClinicalTrials.gg INT000614
- MeSH (NLM) C000614721sembragilineOne source NLM
- UNII (FDA) K3W9672PNJSEMBRAGILINEConfirmed FDA, NLM, Wikidata
- Wikidata Q27281921sembragilineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152331SembragilineOne source FDA
- DrugBank DB20857One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614721 | sembragiline | One source NLM |
| UNII (FDA) | K3W9672PNJ | SEMBRAGILINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27281921 | sembragiline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152331 | Sembragiline | One source FDA |
| DrugBank | DB20857 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.